Sarepta Therapeutics Inc. (SRPT) Given New $76.00 Price Target at Oppenheimer Holdings Inc.
Several other equities research analysts have also recently issued reports on SRPT. JMP Securities upgraded Sarepta Therapeutics to an outperform rating in a research note on Monday. Jefferies Group upgraded Sarepta Therapeutics from an underperform rating to a hold rating and boosted their price target for the company from $7.00 to $50.00 in a research note on Monday. RBC Capital Markets upgraded Sarepta Therapeutics from a sector perform rating to an outperform rating in a research note on Monday. Leerink Swann upgraded Sarepta Therapeutics from an underperform rating to a market perform rating in a research note on Monday. Finally, Royal Bank Of Canada upgraded Sarepta Therapeutics from a sector perform rating to an outperform rating and boosted their price target for the company from $5.00 to $83.00 in a research note on Monday. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the company. Sarepta Therapeutics currently has an average rating of Buy and an average price target of $37.90.
Sarepta Therapeutics (NASDAQ:SRPT) opened at 48.94 on Monday. The company’s market capitalization is $2.34 billion. The firm has a 50-day moving average price of $27.32 and a 200-day moving average price of $21.07. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $56.18.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same period in the prior year, the company posted ($0.87) earnings per share. On average, equities analysts anticipate that Sarepta Therapeutics will post ($5.16) earnings per share for the current fiscal year.
In other news, CEO Edward M. Md Kaye sold 24,557 shares of the stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the transaction, the chief executive officer now owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 10.90% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in SRPT. Teacher Retirement System of Texas boosted its position in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares during the period. Advisor Group Inc. bought a new position in Sarepta Therapeutics during the second quarter worth about $154,000. Quantitative Systematic Strategies LLC bought a new position in Sarepta Therapeutics during the second quarter worth about $211,000. First Allied Advisory Services Inc. boosted its position in Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock worth $245,000 after buying an additional 800 shares during the period. Finally, National Planning Corp boosted its position in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares during the period. 72.09% of the stock is currently owned by institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.